We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARADIGM CORP. ARDM

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Tadsamillionaire1/12/2006 4:34:14 PM
   of 255
Promising events now that the reverse split has taken place...
Wednesday December 21, 8:00 am ET
Supply Chain Qualified and Commercial Manufacturing Line Fully Operational

HAYWARD, CA--(MARKET WIRE)--Dec 21, 2005 -- Aradigm Corporation (NasdaqNM:ARDM - News) today announced the completion of manufacturing of pivotal and clinical batches of its Intraject Sumatriptan product on its commercial-scale manufacturing line. With the successful transfer of technology and analytical methods to the company's Contract-Manufacturing Partners, final product release testing is currently underway and, pending partnering of the product, would be available for a pivotal bioequivalence trial in 2006.

Thursday January 5, 8:15 am ET
HAYWARD, CA--(MARKET WIRE)--Jan 5, 2006 -- Aradigm Corporation (NasdaqNM:ARDMD - News) today announced that it has filed a request for orphan drug designation with the United States Food and Drug Administration (FDA) for its liposomal ciprofloxacin product for the management of cystic fibrosis (CF).

Such designation provides a company with seven years of marketing exclusivity for a selected drug approved by the FDA along with regulatory assistance, reduced filing fees and possible tax credits.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext